| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/27/2015 | CA2572098C B7-dc binding antibody |
| 01/27/2015 | CA2515699C Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| 01/27/2015 | CA2480311C Oligomeric compounds for the modulation of hif-1alpha expression |
| 01/27/2015 | CA2477409C Process for the preparation of hypoallergenic major birch pollen allergen rbet v 1 |
| 01/27/2015 | CA2470104C Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
| 01/27/2015 | CA2298015C Production of erythropoietin by endogenous gene activation |
| 01/22/2015 | WO2015010048A1 Chemically-stabilized a kinase anchoring protein (akap) peptide disruptors |
| 01/22/2015 | WO2015010045A1 Apj receptor compounds |
| 01/22/2015 | WO2015009888A2 Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers |
| 01/22/2015 | WO2015009820A2 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| 01/22/2015 | WO2015009726A2 Medical uses of cd38 agonists |
| 01/22/2015 | WO2015009678A2 Specific targeting of rna expanded repeat sequences |
| 01/22/2015 | WO2015009596A2 Methods and oral formulations for enzyme replacement therapy of human lysosomal and metabolic diseases |
| 01/22/2015 | WO2015009591A2 Treatment for melanoma |
| 01/22/2015 | WO2015009414A1 Methods and compositions for regulating srca2a expression levels in myocardial infarction |
| 01/22/2015 | WO2015009406A1 Methods for promoting neuronal development and/or health |
| 01/22/2015 | WO2015008836A1 Agent for preventing muscle atrophy and/or promoting muscle synthesis |
| 01/22/2015 | WO2015008214A1 Bacterial lysins and uses thereof |
| 01/22/2015 | WO2015008169A2 Device, system and method for delivery of a long-acting drug |
| 01/22/2015 | WO2015008166A2 Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment |
| 01/22/2015 | WO2015008062A1 Anti-pathogen device |
| 01/22/2015 | WO2015007903A1 Targeted modified tnf family members |
| 01/22/2015 | WO2015007887A1 Combination of a ligand of hvem and an immunotoxin for use in therapy |
| 01/22/2015 | WO2015007326A1 Agents comprising a terminal alpha-galactosyl moiety for use in prevention and/or treatment of inflammatory diseases |
| 01/22/2015 | WO2015007216A1 Polypeptide, dna molecule encoding the polypeptide, vector, preparation method and use |
| 01/22/2015 | WO2015006833A1 A method for treating type 1 diabetes |
| 01/22/2015 | US20150025511 Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| 01/22/2015 | US20150025501 Composition and Method for the Treatment or Prevention of Spinal Disorders |
| 01/22/2015 | US20150025496 Swallowable drug delivery device and method of delivery |
| 01/22/2015 | US20150025233 Use of lipid conjugates in the treatment of diseases |
| 01/22/2015 | US20150025224 Antagonists of neuropilin receptor function and use thereof |
| 01/22/2015 | US20150025219 Cyclic pentadepsipeptides and microorganism of fusarium strain producing the same |
| 01/22/2015 | US20150025125 Stresscopins and their Uses |
| 01/22/2015 | US20150025024 Solid Compositions |
| 01/22/2015 | US20150025022 Novel il-17r-ecd mutants |
| 01/22/2015 | US20150025020 Self-preserved oil dispersions comprising boric acid |
| 01/22/2015 | US20150025018 METHOD FOR INHIBITING euPTX3 TO TREAT NASOPHARYNGEAL CARCINOMA BY AMINO ACID SEQUENCE |
| 01/22/2015 | US20150025016 Peptides that inhibit the interaction between asf1 and histones, and use thereof |
| 01/22/2015 | US20150025015 Keratin compositions comprising halofuginone |
| 01/22/2015 | US20150025012 Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
| 01/22/2015 | US20150025011 Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
| 01/22/2015 | US20150025010 Novel albumin-free factor viii formulations |
| 01/22/2015 | US20150025009 Collagen and fibrin microthreads in a discrete thread model of in vitro acl scaffold regeneration |
| 01/22/2015 | US20150025008 Compositions and Methods of Detecting and Treating Neural Tube Defects |
| 01/22/2015 | US20150025007 Methods to reduce scarring |
| 01/22/2015 | US20150025006 Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders |
| 01/22/2015 | US20150025003 Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| 01/22/2015 | US20150025002 Peptides and peptide derivatives based on xenin |
| 01/22/2015 | US20150025001 Fish protein hydrolysate having a satietogenic activity, nutraceutical and pharmacological compositions comprising such a hydrolysate and method for obtaining same |
| 01/22/2015 | US20150025000 Methods for Treating HCV |
| 01/22/2015 | US20150024999 Methods for Treating HCV |
| 01/22/2015 | US20150024995 Combination Of Dopamine Agonists Plus First Phase Insulin Secretagogues For The Treatment Of Metabolic Disorders |
| 01/22/2015 | US20150024994 Use of thymosin alpha for the treatment of sepsis |
| 01/22/2015 | US20150024431 Thrombopoietic compounds |
| 01/22/2015 | US20150024066 Methods for preventing or treating excess weight using oxyntomodulin |
| 01/22/2015 | US20150024051 Injectable hydrogel system to modulate host response at bone implant interface |
| 01/22/2015 | US20150024050 Dry powder formulations of dnase i |
| 01/22/2015 | US20150024031 Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent |
| 01/22/2015 | US20150024030 Protection against and treatment of ionizing radiation |
| 01/22/2015 | US20150024024 Cell Lines That Produce Prostaglandin F2 Alpha (PGF2A) And Uses Thereof |
| 01/22/2015 | US20150024000 Multivalent vaccine protection from staphylococcus aureus infection |
| 01/22/2015 | US20150023989 New antibody drug conjugates (adcs) and the use thereof |
| 01/22/2015 | US20150023988 Potent and selective inhibitors of nav1.7 |
| 01/22/2015 | US20150023987 Immunogenic compositions and reagents for preparing |
| 01/22/2015 | US20150023982 Methods of administering anti-tnfalpha antibodies |
| 01/22/2015 | US20150023981 Method of treatment and agents useful for same |
| 01/22/2015 | US20150023977 Protein formulations and methods of making same |
| 01/22/2015 | US20150023975 PAR-1 Activation by Metalloproteinase-1 (MMP-1) |
| 01/22/2015 | US20150023974 Toll-like receptor 2 binding epitope and binding member thereto |
| 01/22/2015 | US20150023971 Modulation of Activity of Proneurotrophins |
| 01/22/2015 | US20150023961 Methods of modulating immunological responses by administering truncated baff receptors |
| 01/22/2015 | US20150023960 Compositions and Methods of Use for Treating Metabolic Disorders |
| 01/22/2015 | US20150023949 Compositions and methods for diagnosis and treatment of pervasive developmental disorder |
| 01/22/2015 | US20150023947 Medicinal products for the treatment of blood coagulation disorders |
| 01/22/2015 | US20150023946 Combined Use of a Sulfated Glycosaminoglycan and a Hyaluronidase for Improving the Bioavailability of Factor VIII |
| 01/22/2015 | US20150023945 Lysozymes |
| 01/22/2015 | US20150023944 Method of Treating and Diagnosing Parkinson's Disease and Related Dysautonomic Disorders |
| 01/22/2015 | US20150023942 Compositions and methods for promoting neuronal outgrowth |
| 01/22/2015 | US20150023937 Histone deacetylase (hdac) inhibitor up-regulates car expression and targeted antigen intensity, increasing antitumor efficacy |
| 01/22/2015 | US20150023932 Engineered peptide (ep)-directed protein intercellular delivery system and uses thereof |
| 01/22/2015 | US20150023929 Oral unit dosage forms and uses of same for the treatment of gaucher disease |
| 01/22/2015 | US20150023924 Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| 01/22/2015 | US20150023923 Methods for promoting neuronal development and/or health |
| 01/22/2015 | US20150023922 Methods for promoting neuronal development and/or health |
| 01/22/2015 | US20150023921 Hepatitis c antiviral compositions and methods |
| 01/22/2015 | US20150023920 Novel compositions and methods for preventing or treating cancer metastasis |
| 01/22/2015 | US20150023919 Induction of tolerance in lung allograft transplantation |
| 01/22/2015 | US20150023917 Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases |
| 01/22/2015 | US20150023915 Treatment for melanoma |
| 01/22/2015 | US20150023913 Hepatitis C Virus Inhibitors |
| 01/22/2015 | US20150023912 Combinations of albumin-based drug delivery systems |
| 01/22/2015 | US20150023911 Device-based methods for localized delivery of cell-free carriers with stress-induced cellular factors |
| 01/22/2015 | US20150023910 Granulysin in immunotherapy |
| 01/22/2015 | US20150023909 Lymph node-targeting nanoparticles |
| 01/22/2015 | US20150023905 Synthetic mechanical hemostatic composition, method of making and use thereof |
| 01/22/2015 | US20150023874 Folate receptor alpha binding ligands |
| 01/22/2015 | DE69831673C5 Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme Use of exedinen and their antagonists to rundown the food intake |
| 01/21/2015 | EP2826788A1 Targeting complement factor H for treatment of diseases by the sue of CR2-FH molecules |
| 01/21/2015 | EP2826787A1 Therapeutic epitopes and uses thereof |
| 01/21/2015 | EP2826786A1 Advantageous Salts of MU-Opiate Receptor Peptides |